Annamycin, a chemotherapy drug with zero cardiotoxicity, is being tested for relapsed or refractory AML in the phase 3 MIRACLE trial. The trial, active in the U.S., Europe, and the Middle East, ...

Exicure to initiate new clinical trial in acute myeloid leukaemia with GPC-100: Redwood City, California Tuesday, April 15, 2025, 18:00 Hrs [IST] Exicure, Inc., an early-stage bio ...

为解决急性髓系白血病（AML）治疗中寻找优化方案的问题，研究人员开展了维奈克拉 - 高三尖杉酯碱 - 阿糖胞苷（VHA）方案治疗新诊断 AML 患者的研究。结果显示该方案总缓解率达 92.7%，毒性较低。这为 AML 治疗提供了新选择。 在血液疾病的治疗领域，急性髓系 ...

US-based pharmaceutical company Moleculin Biotech has begun dosing subjects in its Phase III MIRACLE trial of Annamycin with ...

However, we found that most acute myeloid leukemia (AML) cells, especially M4 and M5 subtypes, produce TNF and show basal level activation of RIP1/RIP3/MLKL signaling, yet do not undergo necroptosis.

and cytarabine from Sigma-Aldrich (Taufkirchen, Germany). Solutions of BEZ-235 in 10% NMP/90% PEG300 (Roth, Karlsruhe, Germany; Applichem, Darmstadt, Germany) and AC220 in 22% hydroxypropyl-β ...

Venclexta (venetoclax) is already FDA approved in AML in combination with low-dose cytarabine (LDAC) on the basis of early-mid stage trials, but may need confirmatory data from a later stage trial ...

cytarabine, and idarubicin) in patients with R/R AML. Patients received either uproleselan or placebo for 8 days over 1 cycle of induction and, if applicable, up to 3 cycles of consolidation.

today announced the first patient has been dosed in its Phase 3 pivotal trial evaluating Annamycin in combination with Cytarabine (also known as “Ara-C” and for which the combination of Annamycin and ...

This Phase 3 “MIRACLE” trial (derived from Moleculin R/R AML AnnAraC Clinical Evaluation ... in Part A of the trial to receive high dose cytarabine (HiDAC) combined with either placebo ...